Juno licenses gamma secretase inhibitor, related IP

Juno Therapeutics Inc. (NASDAQ:JUNO) announced on Wednesday a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors and tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)-directed chimeric antigen receptor (CAR) T cells.

Under a deal with Eli Lilly and Co. (NYSE:LLY), Juno acquired a license to the pharma's gamma secretase inhibitor LY3039478. The compound is in Phase I testing to treat advanced or metastatic solid tumors and Phase I/II testing to treat T cell acute lymphoblastic leukemia (ALL) and T cell lymphoblastic lymphoma...